R&D | Cutting-edge science and innovative research

News

Windward Bio catches $175m from its IPO

Swiss biotech Windward Bio has raised $175m in its Nasdaq IPO as it prepares to take on some heavyweight rivals with its long-acting TSLP inhibitor.

News

Neurosterix' $105m round leads the week's biotech financings

Neurosterix raises $105m for its schizophrenia candidate, as Delix, VectorY, and Eli Radiopharma also add to their cash reserves.

R&D

Life sciences real estate: Beyond labs

Growth in biotechnology, pharmaceutical R&D, and advanced therapies is driving demand for specialist laboratory space.

R&D

Inspection readiness is now a commercial question

Manufacturers of advanced therapies are discovering that a digital quality system does more than satisfy inspectors.

News

BMS shakes up R&D under CMO Cristian Massacesi

Bristol Myers Squibb is combining its R&D operations into a single unit led by chief medical officer and development head Cristian Massacesi.

News

AbbVie is big pharma’s first mover in ‘in situ’ cell therapy

AbbVie has signed a wide-ranging collaboration with Umoja Biopharma in the area of ‘in situ’ or in vivo cell therapy, an emerging strategy that does away with the need to

News

Merck bets on Inspirna’s colorectal cancer drug ompenaclid

Germany’s Merck KGaA is paying $45 million upfront for rights to a potentially first-in-class drug for colorectal cancer (CRC) being developed by New York biotech Inspirna

R&D

JP Morgan 2024 live event coverage Day 1

JP Morgan Week 2024 - Day 1

After a Monday full of one-on-one meetings and video recordings, Tuesday will see pharmaphorum editor-in-chief Jonah Comstock starting the day at Informa’s Biotech Summit, where he’ll report on ses

Debates & Insights

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Webinars

Sponsored

Synthetic control arms in clinical trials: Making it happen

Across the industry, pharma companies are turning to AI and real-world data to address many of the challenges of running clinical trials.

R&D

Sponsored

How synthetic control arms are changing clinical trials

Clinical trials are involved, expensive, and have been done largely the same way for decades but with today’s technology all that can change. With drawn-out timelines and billions

News

Windward Bio catches $175m from its IPO

Swiss biotech Windward Bio has raised $175m in its Nasdaq IPO as it prepares to take on some heavyweight rivals with its long-acting TSLP inhibitor.

News

Neurosterix' $105m round leads the week's biotech financings

Neurosterix raises $105m for its schizophrenia candidate, as Delix, VectorY, and Eli Radiopharma also add to their cash reserves.

Press Releases

Media Partner

PHARMAP 2027 Addresses the Future of Pharmaceutical Manufact...

Senior pharma professionals gather in Berlin on 19-20 April for the Pharmaceutical Manufacturing and Packaging Congress (PHARMAP) 2027

Press Releases

Partner Content

The Evolution Summit Announces September 2026 Program for Cl...

Marcus Evans announces The Evolution Summit, taking place September 28-29, 2026 at Park Hyatt Aviara Resort, Golf Club & Spa, San Diego, CA.

Views & Analysis

R&D

Life sciences real estate: Beyond labs

Growth in biotechnology, pharmaceutical R&D, and advanced therapies is driving demand for specialist laboratory space.

R&D

Inspection readiness is now a commercial question

Manufacturers of advanced therapies are discovering that a digital quality system does more than satisfy inspectors.

R&D

A certificate of analysis should be evidence, not a sales do...

Regulators weighing peptide bulk substances can ask whether today's documentation rules fit the risks of this supply chain.

Deep Dive

R&D

Cancer misinformation is a trust problem, not just an inform...

R&D

The GLP-1 Reckoning

R&D

Designing obesity trials around real lives: How patient cent...

R&D

From obesity to outcomes abstract visual

Sponsored

The future of cardiometabolic trials: From obesity to outcom...

Gain practical insight into how leading experts are designing the next generation of cardiometabolic trials in an upcoming webinar from hVIVO

R&D

Sponsored

Exploring the future: Opportunities and challenges in cell a...

Rare disease treatment poses distinct challenges for physicians, patients, caregivers, and pharma companies.

R&D

Sponsored

Beyond clinical: Boosting recruitment and retention with SDO...

The success of clinical trials hinges on a complex array of factors, many of which extend beyond traditional clinical care.

Podcasts

R&D

pharmaphorum podcast Episode 278, Shai Melcer, IIA

Bioconvergence & future human health, with Shai Melcer

Shai Melcer discusses bioconvergence, a multidisciplinary research and development approach that merges technologies.

R&D

pharmaphorum podcast Episode 272, Dr Harpreet Singh, Precision for Medicine

Understanding Operation Trialblazer, with Dr Harpreet Singh

Dr Harpreet Singh, CMO at Precision for Medicine, brings both an insider and outsider perspective to discussing Operation TRIALBLAZER.

R&D

Prevent-Stop-Cure: Diagnostics & chronic liver disease, with...

Video

R&D

Boosting biotech in Basel – with Valentina Francia

pharmaphorum speaks with Valentina Francia from Basel Area Business and Innovation about why many life sciences startups are finding success in Basel.

R&D

Sponsored

Beyond recruitment: Creating patient engagement that lasts

In the final episode of our patient- and site-centric solutions interview series, Zoltan Varga discusses the importance of PRE.

R&D

LSX 2026 with Sam Possemiers, MRM Health

Taking the microbiome seriously, with Sam Possemiers

pharmaphorum catches up with MRM Health founder and CEO Sam Possemiers at LSX 2026.

White Papers

R&D

Sponsored

From Alzheimer’s disease research to the real-world setting:...

In a new white paper, Lucid Strategy Consulting suggests three key themes for pharma strategists seeking market leadership in the Alzheimer's space.

R&D

Sponsored

A data-driven guide to small molecule drug discovery and dev...

A new white paper from Excelra takes a closer look at how discovery teams actually experience the small molecule development journey.

R&D

A man stood on a rock looking towards the horizon

Sponsored

A New Framework to Engineer Breakthrough Value for Medicines

A new white paper from Lumanity – ‘A New Framework to Engineer Breakthrough Value for Medicines: Value Inflection Points Across the Development Path’.

Event

Partner Content

Rational Based Drug Design Summit Europe

Driving Safer, Faster & More Efficient Discovery Across Europe

Event

Partner Content

Europe's Largest Gathering for ADC Innovation

Taking place in London from 8-11 March 2027, the 17th World ADC London returns as Europe's largest annual gathering dedicated to the ADC community

Event

3rd Annual Personalized Cancer Vaccine Summit 2026 | Decembe...

The 3rd Annual Personalized Cancer Vaccine Summit brings together leaders from across companies to share data-driven insights

Partner Content

Rational Based Drug Design Summit Europe

Driving Safer, Faster & More Efficient Discovery Across Europe

Event

Partner Content

Europe's Largest Gathering for ADC Innovation

Taking place in London from 8-11 March 2027, the 17th World ADC London returns as Europe's largest annual gathering dedicated to the ADC community

Event

3rd Annual Personalized Cancer Vaccine Summit 2026 | Decembe...

The 3rd Annual Personalized Cancer Vaccine Summit brings together leaders from across companies to share data-driven insights

Windward Bio catches $175m from its IPO

Neurosterix' $105m round leads the week's biotech financings

Life sciences real estate: Beyond labs

Inspection readiness is now a commercial question

BMS shakes up R&D under CMO Cristian Massacesi

AbbVie is big pharma’s first mover in ‘in situ’ cell therapy

Merck bets on Inspirna’s colorectal cancer drug ompenaclid

JP Morgan Week 2024 - Day 1

Synthetic control arms in clinical trials: Making it happen

How synthetic control arms are changing clinical trials

Windward Bio catches $175m from its IPO

Neurosterix' $105m round leads the week's biotech financings

PHARMAP 2027 Addresses the Future of Pharmaceutical Manufact...

The Evolution Summit Announces September 2026 Program for Cl...

Life sciences real estate: Beyond labs

Inspection readiness is now a commercial question

A certificate of analysis should be evidence, not a sales do...

Cancer misinformation is a trust problem, not just an inform...

The GLP-1 Reckoning

Designing obesity trials around real lives: How patient cent...

The future of cardiometabolic trials: From obesity to outcom...

Exploring the future: Opportunities and challenges in cell a...

Beyond clinical: Boosting recruitment and retention with SDO...

Bioconvergence & future human health, with Shai Melcer

Understanding Operation Trialblazer, with Dr Harpreet Singh

Prevent-Stop-Cure: Diagnostics & chronic liver disease, with...

Boosting biotech in Basel – with Valentina Francia

Beyond recruitment: Creating patient engagement that lasts

Taking the microbiome seriously, with Sam Possemiers

From Alzheimer’s disease research to the real-world setting:...

A data-driven guide to small molecule drug discovery and dev...

A New Framework to Engineer Breakthrough Value for Medicines

Rational Based Drug Design Summit Europe

Europe's Largest Gathering for ADC Innovation

3rd Annual Personalized Cancer Vaccine Summit 2026 | Decembe...

Rational Based Drug Design Summit Europe

Europe's Largest Gathering for ADC Innovation

3rd Annual Personalized Cancer Vaccine Summit 2026 | Decembe...

Closing the global evidence gap in oncology, with Flatiron H...

Securing your ROI: Turning post-acquisition integration into...

Debates & Insights

News

Press Releases

Editor's Picks

Views & Analysis

Deep Dive

Webinars

Podcasts

Video

White Papers

Event

Partner Content

Editor's Picks